150 related articles for article (PubMed ID: 31816122)
1. Second cancers in MPN: Survival analysis from an international study.
Marchetti M; Ghirardi A; Masciulli A; Carobbio A; Palandri F; Vianelli N; Rossi E; Betti S; Di Veroli A; Iurlo A; Cattaneo D; Finazzi G; Bonifacio M; Scaffidi L; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; Elli EM; Palova M; Rapezzi D; Erez D; Gomez M; Wille K; Perez-Encinas M; Lunghi F; Angona A; Fox ML; Beggiato E; Benevolo G; Carli G; Cacciola R; McMullin MF; Tieghi A; Recasens V; Isfort S; Pane F; De Stefano V; Griesshammer M; Alvarez-Larran A; Vannucchi AM; Rambaldi A; Barbui T
Am J Hematol; 2020 Mar; 95(3):295-301. PubMed ID: 31816122
[TBL] [Abstract][Full Text] [Related]
2. Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study.
Hultcrantz M; Wilkes SR; Kristinsson SY; Andersson TM; Derolf ÅR; Eloranta S; Samuelsson J; Landgren O; Dickman PW; Lambert PC; Björkholm M
J Clin Oncol; 2015 Jul; 33(20):2288-95. PubMed ID: 26033810
[TBL] [Abstract][Full Text] [Related]
3. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
Barbui T; Ghirardi A; Masciulli A; Carobbio A; Palandri F; Vianelli N; De Stefano V; Betti S; Di Veroli A; Iurlo A; Cattaneo D; Delaini F; Bonifacio M; Scaffidi L; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; Elli EM; Palova M; Bertolotti L; Erez D; Gomez M; Wille K; Perez-Encinas M; Lunghi F; Angona A; Fox ML; Beggiato E; Benevolo G; Carli G; Cacciola R; McMullin MF; Tieghi A; Recasens V; Marchetti M; Griesshammer M; Alvarez-Larran A; Vannucchi AM; Finazzi G
Leukemia; 2019 Aug; 33(8):1996-2005. PubMed ID: 31142846
[TBL] [Abstract][Full Text] [Related]
4. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms.
De Stefano V; Carobbio A; Di Lazzaro V; Guglielmelli P; Iurlo A; Finazzi MC; Rumi E; Cervantes F; Elli EM; Randi ML; Griesshammer M; Palandri F; Bonifacio M; Hernandez-Boluda JC; Cacciola R; Miroslava P; Carli G; Beggiato E; Ellis MH; Musolino C; Gaidano G; Rapezzi D; Tieghi A; Lunghi F; Loscocco GG; Cattaneo D; Cortelezzi A; Betti S; Rossi E; Finazzi G; Censori B; Cazzola M; Bellini M; Arellano-Rodrigo E; Bertozzi I; Sadjadian P; Vianelli N; Scaffidi L; Gomez M; Cacciola E; Vannucchi AM; Barbui T
Blood Cancer J; 2018 Feb; 8(3):25. PubMed ID: 29535299
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms.
Potthoff A; Attia D; Pischke S; Mederacke I; Beutel G; Rifai K; Deterding K; Heiringhoff K; Klempnauer J; Strassburg CP; Manns MP; Bahr MJ
Liver Int; 2015 Aug; 35(8):2042-9. PubMed ID: 25736096
[TBL] [Abstract][Full Text] [Related]
6. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
De Stefano V; Ghirardi A; Masciulli A; Carobbio A; Palandri F; Vianelli N; Rossi E; Betti S; Di Veroli A; Iurlo A; Cattaneo D; Finazzi G; Bonifacio M; Scaffidi L; Patriarca A; Rumi E; Casetti IC; Stephenson C; Guglielmelli P; Elli EM; Palova M; Rapezzi D; Erez D; Gomez M; Wille K; Perez-Encinas M; Lunghi F; Angona A; Fox ML; Beggiato E; Benevolo G; Carli G; Cacciola R; McMullin MF; Tieghi A; Recasens V; Isfort S; Marchetti M; Griesshammer M; Alvarez-Larran A; Vannucchi AM; Rambaldi A; Barbui T
Blood; 2020 Jan; 135(5):381-386. PubMed ID: 31869407
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre.
Deschamps P; Moonim M; Radia D; Curto-Garcia N; Woodley C; Bassiony S; O'Sullivan J; Harrington P; Raj K; Francis Y; Kordasti S; Ali S; Harrison CN; McLornan DP
Br J Haematol; 2021 May; 193(4):792-797. PubMed ID: 33751548
[TBL] [Abstract][Full Text] [Related]
8. Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
Krahling T; Balassa K; Kiss KP; Bors A; Batai A; Halm G; Egyed M; Fekete S; Remenyi P; Masszi T; Tordai A; Andrikovics H
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):98-104. PubMed ID: 26487696
[TBL] [Abstract][Full Text] [Related]
9. Recent decline in the U.S. death rate from myeloproliferative neoplasms, 1999-2006.
Polednak AP
Cancer Epidemiol; 2012 Apr; 36(2):133-6. PubMed ID: 21846594
[TBL] [Abstract][Full Text] [Related]
10. Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review.
Marchetti M; Carobbio A; Capitoni E; Barbui T
Am J Hematol; 2018 May; 93(5):698-703. PubMed ID: 29377227
[TBL] [Abstract][Full Text] [Related]
11. US death rates from myeloproliferative neoplasms, and implications for cancer surveillance.
Polednak AP
J Registry Manag; 2011; 38(2):87-92. PubMed ID: 22096879
[TBL] [Abstract][Full Text] [Related]
12. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients.
Landtblom AR; Bower H; Andersson TM; Dickman PW; Samuelsson J; Björkholm M; Kristinsson SY; Hultcrantz M
Leukemia; 2018 Oct; 32(10):2203-2210. PubMed ID: 29535425
[TBL] [Abstract][Full Text] [Related]
13. Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.
Wang JC; Chen C; Kundra A; Kodali S; Pandey A; Wong C; Cheung T; Gotlieb V; Joseph G; Tribie S
Leuk Res; 2019 Apr; 79():52-59. PubMed ID: 30851544
[TBL] [Abstract][Full Text] [Related]
14. Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies.
Schuler E; Boughoufala S; Rautenberg C; Nachtkamp K; Dienst A; Fenk R; Haas R; Kondakci M; Germing U; Schroeder T; Kobbe G
Ann Hematol; 2019 May; 98(5):1225-1235. PubMed ID: 30923997
[TBL] [Abstract][Full Text] [Related]
15. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
Douglas G; Harrison C; Forsyth C; Bennett M; Stevenson W; Hounsell J; Ratnasingam S; Ritchie D; Ross DM; Grigg A
Leuk Lymphoma; 2017 Jan; 58(1):89-95. PubMed ID: 27454522
[TBL] [Abstract][Full Text] [Related]
16. A monocentric retrospective study of 138 therapy-related myeloid neoplasms.
Claerhout H; Lierman E; Michaux L; Verhoef G; Boeckx N
Ann Hematol; 2018 Dec; 97(12):2319-2324. PubMed ID: 30203335
[TBL] [Abstract][Full Text] [Related]
17. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
Martinelli I; De Stefano V; Carobbio A; Randi ML; Santarossa C; Rambaldi A; Finazzi MC; Cervantes F; Arellano-Rodrigo E; Rupoli S; Canafoglia L; Tieghi A; Facchini L; Betti S; Vannucchi AM; Pieri L; Cacciola R; Cacciola E; Cortelezzi A; Iurlo A; Pogliani EM; Elli EM; Spadea A; Barbui T
Am J Hematol; 2014 Nov; 89(11):E200-5. PubMed ID: 25042466
[TBL] [Abstract][Full Text] [Related]
18. Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.
Sengsayadeth S; Gatwood KS; Boumendil A; Labopin M; Finke J; Ganser A; Stelljes M; Ehninger G; Beelen D; Niederwieser D; Blaise D; Dreger P; Mufti G; Chevallier P; Mailhol A; Gilleece MH; Gorin N; Esteve J; Ciceri F; Baron F; Schmid C; Giebel S; Mohty M; Savani BN; Nagler A
Blood Adv; 2018 Aug; 2(16):2127-2135. PubMed ID: 30143527
[TBL] [Abstract][Full Text] [Related]
19. Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study.
Osca-Gelis G; Puig-Vives M; Saez M; Gallardo D; Lloveras N; Guàrdia R; Marcos-Gragera R
Leuk Lymphoma; 2015 Apr; 56(4):896-902. PubMed ID: 25058372
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics of patients with multiple primary neoplasms-a retrospective analysis.
Nemes A; Todor N; Nagy V
J BUON; 2018; 23(6):1846-1854. PubMed ID: 30610812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]